| Autor: |
Sossau D; Dermatology Department, University Hospital Tubingen, Tubingen, Germany., Kofler L, Eigentler T |
| Jazyk: |
angličtina |
| Zdroj: |
Melanoma research [Melanoma Res] 2017 Oct; Vol. 27 (5), pp. 516-518. |
| DOI: |
10.1097/CMR.0000000000000381 |
| Abstrakt: |
Interferon-α (INF-α) is used as an adjuvant treatment for high-risk cutaneous melanoma. It has a large variety of potentially severe and irreversible side effects and can contribute toward the development of autoimmune disease. We report a case of a 59-year-old woman who developed type 1 diabetes following the use of low-dose IFN-α for the adjuvant treatment of stage IIB melanoma. Fifteen months after initiating IFN-α, she presented with blood glucose of 1126 mg/dl, hyponatremia, and microalbuminuria. Antibodies to glutamic acid decarboxylase and islet antigen-2 were negative and C-peptide was markedly reduced. There was no personal or family history of any autoimmune conditions. Reinforced insulin treatment and volume substitution with saline and glucose as a counter-regulation was started. To the best of our knowledge, this is the first reported case of low-dose IFN-α-induced type 1 diabetes. Clinicians should closely evaluate the pros and cons of IFN-α treatment in an adjuvant setting and remain mindful of the possibility of drug-induced autoimmune disease. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
